IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Clinical trial NCT05780307 · UNKNOWN

Trial details

NCT number: NCT05780307
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor Non-small Cell Lung Cancer Small Cell Lung Cancer Breast Cancer Squamous Cell Cancer of Head and Neck Colorectal Cancer

Start date: 2023-03-23
Primary completion: 2024-03-10
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.